Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tnx-801 save search
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Published: 2024-02-08 (Crawled : 01:00) - globenewswire.com
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: -64.03%
H: 9.16%
C: -1.17%
tnx-103 first treatment hypertension heart therapeutics study
Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Published: 2023-10-31 (Crawled : 21:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: -18.64%
H: 4.15%
C: 2.06%
tnx-601 treatment pharmaceuticals topline results study
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder
Published: 2023-10-16 (Crawled : 11:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 0.33%
H: 2.27%
C: -2.34%
tnx-601 treatment pharmaceuticals study
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox
Published: 2023-08-21 (Crawled : 11:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: 0.0%
tnx-801 fda vaccine pharmaceuticals smallpox meeting potential results
Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia
Published: 2023-08-01 (Crawled : 11:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: -2.68%
H: 0.92%
C: -5.5%
tnx-102 management fibromyalgia pharmaceuticals trial
Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023
Published: 2023-07-26 (Crawled : 20:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 5.81%
H: 0.0%
C: -2.2%
tnx-601 expected pharmaceuticals topline study
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression
Published: 2023-05-17 (Crawled : 11:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 0.0%
H: 11.27%
C: -1.05%
tnx-601 reveal active depression pharmaceuticals results molecular
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘UPLIFT’ Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD)
Published: 2023-03-16 (Crawled : 12:20) - biospace.com/
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 2.3%
H: 5.04%
C: 4.24%
tnx-601 treatment pharmaceuticals study major depressive disorder
Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Company’s Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801)
Published: 2023-02-09 (Crawled : 13:00) - biospace.com/
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 1.63%
H: 1.6%
C: -11.2%
tnx-801 pharmaceuticals monkeypox smallpox vaccine publication
Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress
Published: 2022-12-01 (Crawled : 12:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: -1.3%
H: 2.76%
C: -0.26%
tnx-801 pharmaceuticals monkeypox smallpox immunotherapy vaccine presentation potential update
Tonix Pharmaceuticals Announces IND Clearance for TNX-601 ER as a Potential Treatment for Major Depressive Disorder
Published: 2022-10-03 (Crawled : 07:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 3.0%
H: 12.68%
C: -0.06%
tnx-601 treatment clearance pharmaceuticals potential major depressive disorder
Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain
Published: 2022-08-01 (Crawled : 23:00) - biospace.com/
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 21.43%
H: 4.9%
C: -8.82%
tnx-1900 treatment patent oxytocin
Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox Infection
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 5.62%
H: 11.83%
C: 10.65%
tnx-801 monkeypox smallpox research collaboration vaccine infection
Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive Disorder
Published: 2022-07-11 (Crawled : 16:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 0.6%
H: 1.78%
C: -9.52%
tnx-601 treatment potential major depressive disorder
Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology
Published: 2022-06-08 (Crawled : 12:20) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: -0.44%
H: 4.4%
C: 0.0%
tnx-801 monkeypox vaccine symposium presentation
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology
Published: 2022-06-01 (Crawled : 02:00) - globenewswire.com
TNXP | $0.1574 1.29% 1.27% 1.6M
|
Health Technology
|
| O: 45.9%
H: 0.0%
C: 0.0%
tnx-801 monkeypox patent smallpox vaccine technology virus platform
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
Published: 2022-05-25 (Crawled : 13:00) - biospace.com/
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: -3.3%
tnx-201 treatment hypertension therapeutics potential
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: -9.06%
H: 16.91%
C: 15.22%
tnx-201 treatment hypertension therapeutics
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs
Published: 2022-01-04 (Crawled : 15:30) - biospace.com/
TENX | $3.59 0.84% 0.84% 12K
|
Health Technology
|
| O: 7.21%
H: 22.64%
C: -15.13%
tnx-102 therapeutics
Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021
Published: 2021-11-22 (Crawled : 14:00) - biospace.com/
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 4.0%
H: 0.0%
C: -3.08%
cancer phase 3 breast cancer metastatic breast cancer
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.